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Abstract
Background: The context and aim of this article was to investigate whether the expression level of Pin1 was in
association with the clinical stage of papillary thyroid carcinomas.
Methods: Seventy-two patients who had been treated at the Affiliated Hospital of Qingdao University – Yantai
YuHuangDing Hospital during January 2013 to December 2014 were rolled in. The expression levels of Pin1 using
immunohistochemistry were tested and were divided into four groups according to the different clinical stages and
final scores based on multiplying intensity and percentage value of IHC results. Data was analyzed with SPSS 20.0,
and P value <0.05 had been chosen as significant.
Results: Considered from analysis result, the Pin1 expression status statistically significantly correlated with the PTC
clinical stages (χ2 = 8.128, P = 0.043); as the clinical stage proceeded, the intensity of Pin1 in PTC cells had been increased.
But we did not find any relationships between immunohistochemical staining results and other clinicopathological
characteristics.
Conclusions: The PTC cells’ intensity of Pin1 was in association with the clinical stage. The role played by Pin1 in PTC
has been studied, and we need to further investigate the application of Pin1 in the treatment of PTC.
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Background
Thyroid cancer constitutes only 1 % of all epithelial ma-
lignancies worldwide, and it is the most frequent endo-
crine neoplasms [1]; at present, the incidence of thyroid
cancer continues to increase, and papillary thyroid can-
cer (PTC) is the most common histological type of thy-
roid malignance [2]. The majority of thyroid cancers has
a good prognosis after appropriate treatment including
surgical procedure, adjuvant radioactive iodine, and TSH
suppression therapy. However, the recurrence rate of dif-
ferentiated thyroid cancer increased up to 30 %, and the
death rate was 8 % after initial treatment at 30 years of
follow-up [3, 4].
Pin1 is a peptidyl prolyl cis-trans isomerase that
specifically binds to the phosphoserine-proline or
phosphothreonine-proline motifs of numerous pro-
teins [5]. Pin1 is vigorously overexpressed in diverse
of human cancers, such as breast and prostate cancer
[6, 7], required for activity and cross-talk of onco-
genic pathways [8]. It has also been linked to several
other diseases that include Alzheimer’s disease and
asthma [9].
It has been well-known that Pin1, acting as an amplifier
of phosphorylation signals, regulates a great deal of cell
functions, mainly through biological processes such as cell
cycle control, centrosome amplification, chromosome in-
stability, transcriptional regulation, RNA processing, cell
proliferation and differentiation, and various pathological
conditions, and may correlate with poor clinical outcomes
[10–12]. Simultaneously, Pin1 has been shown to catalyze
substrate dephosphorylation [13–15], regulate protein sta-
bility and ubiquitination [16, 17], and influence cellular
localization of its targets in vivo [15, 18].
There are some pharmacological experiments which
showed inhibition of Pin1 in vitro triggered apoptosis or
suppressed the gene expression [19, 20]. All those out-
comes indicated that the Pin1 gene plays an oncogenic
role in tumorigenesis, and we could make use of it for
cancer treatment.
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Previous researches have rarely been done to inves-
tigate the relationship between Pin1 and papillary thy-
roid carcinomas (PTCs); Masahiro et al. [21]
confirmed Pin1 mRNA expression in PTC by RT-PCR
in their investigation, and they pointed out that Pin1
immunoreactivity was significantly higher in PTC
than in follicular adenomas (FAs), the same with
Andrzej et al. study [22]. In our study, we investi-
gated whether the expression pattern of Pin1 was dif-
ferent in distinct PTC stage.
Methods
Patients
Seventy-two participants who had been treated at the
Affiliated Hospital of Qingdao University – Yantai
YuHuangDing Hospital from January 2014 to December
2014 were enrolled if they met the following criteria: I:
had settled in Yantai, Shandong Province, permanently,
suffered from PTC, and untreated before (such as drugs,
surgeries); II: finished the clinical examinations including
ultrasonography of the thyroid and neck; III: undergone
thyroid surgery by the same operation team; IV: revealed
that all malignant tumors were PTCs by postoperative
histopathological analysis; V: excluded patients with
metastatic disease (M1) and staged 72 patients according
to the 2014 NCCN Guidelines.
Methods
Immunohistochemistry
The expression levels of Pin1 were detected by
immunohistochemistry.
The 3-μm-thick sections of formalin-fixed, paraffin-
embedded tissues of PTC specimens were placed on
slides and then tested. The expression of Pin1 was de-
tected by Pin1 antibody rabbit polyclonal IgG (sc-15340;
Santa Cruz Biotechnologies, Santa Cruz, CA, USA). The
sections were processed for immunohistochemistry by
deparaffinization in Xylene and dehydration through
graded alcohols. Antigen retrieval was done in citrate
buffer pH 6 by heating the sections at 500 W for 20 min
in a microwave oven. The slides were taken out and left
it to cool and then washed by TBS. Endogenous peroxid-
ase activity was blocked with 3 % H2O2 for 10 min. After
being washed by TBS ,the serial sections were covered
by 3 % BSA at 37 °C in a humid chamber for 1 h and
then incubated overnight in the humid chamber, at 4 °C
with primary antibodies for Pin1 (1:100). The slides were
then briefly washed with TBS and incubated with polymer-
based EnVisionTM (ZB-2301 and peroxidase-conjugated
affinipure goat anti-rabbit IgG (H + L) ,ZSGB-BIO) for 1 h
at 37 °C in the humid chamber. The chromogenic
visualization reaction was done by diaminobenzidine (DAB,
ZSGB-BIO), counterstained with hematoxylin, mounted,


























Table 2 Pin1 expression details with different clinical stages
Group I II III IVA
Negative 2 0 0 0 χ2 = 8.128
Mild 18 0 5 1 df = 3
Moderate 18 1 4 1 P = 0.043
Intense 9 2 7 4
Total 47 3 16 6 72
Table 3 Pin1 expression details with age
Group Negative Mild Moderate Intense Total P value
<45 0 11 7 11 29 0.725
≥45 2 12 17 12 43
Table 4 Pin1 expression details with gender
Group Negative Mild Moderate Intense Total P value
Male 0 7 5 6 18 0.94
Female 2 16 19 17 54
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and then examined by a light microscope (Leica Mcrosys-
tems, Wetzlar GmbH). We did not choose positive control;
while in the negative control, primary antibody was re-
placed by TBS.
Evaluation of immunohistochemical staining
In the present study, we scored the number of PTC-
positive immunostained cells out of 500 in 5 random high-
power fields (Leica Mcrosystems, Wetzlar GmbH, ×400);
the score criterion was described as follows: protein ex-
pression was first semi-quantified by the intensity of stain-
ing: 0 when negative staining if there is total absence; 1
when mild; 2 when moderate, and 3 when intense positive
staining. Positive PTC cells were scored based on nucleus
and cytoplasm staining of Pin1 protein. Pin1 expression
was classified semi-quantitatively using the following cri-
teria: 0 when <5 % of PTC cells expressed Pin1 in the nu-
cleus and cytoplasm; 1 when ≥5 to <25 %; 2 when ≥25 %
to <50 %; and 3 when ≥50 %. Resulting score was calcu-
lated by multiplying intensity and percentage value, and
the final score of immunohistochemical (IHC) staining
ranged from 0 to 9. Based on multiplication score, the
evaluation standard was reformed: 0 (negative; IHC score
0), 1 (mild; IHC score 1–3), 2 (moderate; IHC score 4–6),
or 3 (intense; IHC score 7–9).
Data analysis
Statistical analysis was performed by SPSS 20.0 statistical
software. The Kruskal-Wallis Test was performed for
determining the association between Pin1 protein
expression and PTC clinical stage.
We tried to figure out whether influence was exited with
clinicopathological characteristics (age, gender, family his-
tory, muscle invasion, diameter of cancer, and lymph node
metastasis) and Pin1 expression, and Mann–Whitney U
Test was used to make an access.
The results were considered statistically significant
if P values were <0.05.
Results
In the current study, we performed immunohistochemistry
to examine Pin1 expression in PTC tissues. Clinicopatho-
logical features of 72 PTC patients are described in Table 1,
and the Pin1 expression details are described in Tables 2, 3,
4, 5, 6, 7, and 8.
All patients had taken operation and confirmed with
PTC by histopathological analysis; written consents were
gotten from all patients.
As we can see in Table 1, there were a total of 72
patients enrolled in this investigation, 29 (40.28 %)
were <45 years old and 43 (59.72 %) were ≥45 years;
54 (75 %) females versus 18 (25 %) males; 4 (5.56 %)
with family history and 68 (94.44 %) without; 10
(13.89 %) cases of muscle invasion and 62 (86.11 %)
not; micro-PTCs (diameter ≤1 cm) were found in 27
(37.5 %) cases, and 45 (62.5 %) were >1 cm; 36
(50 %) patients presented lymph node metastasis, and
36 (50 %) did not.
According to the 2014 NCCN Guidelines, 72 pa-
tients were divided into four groups on the basis of
their clinical data: 47 patients (65.28 %) had stage I
disease, 3 (4.12 %) had stage II disease, 16 (22.22 %)
had stage III disease, and 6 (8.33 %) had stage IVA
disease. The correlation of immunohistochemical staining
results with clinical stages is shown in Table 2, with other
clinicopathological characteristics (age, gender, family his-
tory, muscle invasion, diameter of cancer, and lymph node
metastasis) shown in Tables 3, 4, 5, 6, 7, and 8. The results
showed that 70 (97.22 %) PTC sections were positively
stained and 2 (2.78 %) were negatively stained. Of the 72
cases, the Pin1 expression was negative (Fig. 1d) in 2
(2.78 %), mild (Fig. 1a) in 24 (33.33 %), moderate (Fig. 1b)
in 24 (33.33 %), and intense (Fig. 1c) in 22 (30.56 %); the
statistical analysis showed χ2 = 8.128 and P = 0.043. There-
fore, the expression of Pin1 was positively correlated with
clinical stage in PTCs. We suggested that with the clinical
stage proceeding, the intensity of Pin1 in PTC cells had
been increased. But we did not find any relationships
between immunohistochemical staining results and age,
Table 5 Pin1 expression details with family history
T
Group Negative Mild Moderate Intense Total P value
Yes 0 1 2 1 4 0.917
No 2 22 22 22 68
Table 6 Pin1 expression details with muscle invasion
Group Negative Mild Moderate Intense Total P value
Yes 0 6 2 2 10 0.149
No 2 17 22 21 62
Table 7 Pin1 expression details with diameter of cancer
Group Negative Mild Moderate Intense Total P value
≤1 cm 1 7 8 11 27 0.297
>1 cm 1 16 16 12 45
Table 8 Pin1 expression details with lymph node metastasis
Group Negative Mild Moderate Intense Total P value
Yes 2 8 15 11 36 0.682
No 0 15 9 12 36
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gender, family history, muscle invasion, diameter of cancer,
and lymph node metastasis.
Discussion
There have been few published articles about Pin1 ex-
pression in thyroid carcinoma, especially in PTC. In our
investigation, we believed this is the first published art-
icle about Pin1 expression status specialized in PTC
through IHC method, and interestingly, we find Pin1 is
believed to have statistically significantly correlated with
the PTC clinical stages.
Although there have been some opposed voices that
the Pin1 promoter polymorphism is not associated with
risk of cancer, indicating that this polymorphism is not a
biomarker for susceptibility to cancer [23], we believed
identification of Pin1 that were differentially expressed
in diverse PTC specimens may be important to predict
patient’s prognosis and to develop novel therapeutic
strategies for individual treatment.
In the present study, we investigated the expressions
of Pin1 in PTCs. The grades of Pin1 expressions are dis-
criminated and scored in PTCs, as we can see in our re-
sults. According to the results, we showed that Pin1
upregulation was associated with advanced stage in
PTC, but not with other clinicopathological characteris-
tics (age, gender, family history, muscle invasion, diam-
eter of cancer, and lymph node metastasis). Pin1 is
believed to have statistically significantly correlated with
the PTC clinical stages. There is a similar result worked
on esophageal squamous cell carcinoma which had been
published by Lin et al. They had explained that Pin1
positively regulated β-catenin and cyclin D1, and they
proved that knockdown Pin1 can inhibit aggressiveness
of esophageal squamous cell carcinoma (ESCC) cells
[24].
It had been reported that Pin1 was not an oncogene itself,
but it can serve as a translator and amplifier; play a crucial
role in the process of transforming an oncogene to the
signal of cell proliferation, differentiation, and apoptosis;
and is upregulated in various types of tumor tissues [11].
In Masahiro et al. reports, strong correlation between
Pin1 and cyclin D1 immunoexpression and/or cyclin D1
mRNA and Pin1 expression via interaction with Wnt
signaling pathway has been observed, and it has been
suggested that Pin1 may promote cyclin D1 overexpres-
sion directly or through accumulation of beta-catenin in
thyroid cancer cells [21].
Andrzej et al. [22] found statistically significant differ-
ences in expression of Pin1 messenger RNA (mRNA)
between PTC group and benign thyroid lesions (FA,
NG), with real-time relative quantification PCR assay for
Pin1 mRNA expression, and they have confirmed over-
expression of Pin1 gene in PTC. Moreover, no correla-
tions were found between Pin1 expression level and
patients’ sex, age, or tumor size in the PTC group, which
is the same with our results.
Pin1 catalyzes cis-to-trans conformational switches of the
phospho Ser/Thr-Pro (pS/T- Pro) motif in proteins, facili-
tating kinds of signaling pathways which potentates mul-
tiple oncogenic signaling pathways during carcinogenesis
Fig. 1 a–d Immunohistochemical staining present in the expression of Pin1 in different PTC tissues. Pin1 immunohistochemical staining of formalin-fixed,
paraffin-embedded tissue sections of PTC tissues(Leica Mcrosystems, Wetzlar GmbH, ×400). a Sections of PTCs showing mild immunoreactivity of Pin1
protein expression. b Immunoreactivity of Pin1 protein expression was moderate in sections of PTCs. c Immunoreactivity of Pin1 protein expression
showing intense positive staining in PTC tissues. d Pin1 expression was not observed in PTC sections
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[25–27]. It regulates many proteins and factors which are
necessary for the mitosis of normal cells [19, 27–29]. How-
ever, the overexpression of Pin1 can amplify multiple onco-
genic signaling pathways, including Ras [30] and cytokine
NF-κB [31]. As a result of its interactions with so many
protein and factors, Pin1 plays a complicated role in the
regulatory and phosphoproteomic networks [32]. With no
surprise, the increased activity of Pin1 is closely associated
with many kinds of cancers as mentioned above [6, 7].
Thanks to Pin1’s complicated networks with so many
pathways in plenty of cancer cells, drug companies such
as Pfizer Global R&D [33–35] and Vernalis Ltd [36, 37]
as well as several academic laboratories [38–42] have de-
veloped some anti-cancer therapy targeting Pin1. Yoon
et al. had suggested Pin1 could be developed as a major
therapeutic target in many skeletal diseases [5]. In this
article, we also consider its inactivation constituting a
promising therapeutic strategy for cancer patients, and
we believed that targeting Pin1 pathway could represent
a novel modality for treating PTC patients.
There were still some defects in our clinical research,
some improvement measures needed to be made, such
as enlarge the studies scale in polycentric hospitals and
standardized treatment methods. Investigations of the
gene-environmental interaction may give us a better
understanding of the roles of Pin1 polymorphisms in
human cancers.
Conclusions
In the present study, Pin1 upregulation was suggested to
be associated with advanced stage in PTC but not with
other clinicopathological characteristics (age, gender,
family history, muscle invasion, diameter of cancer, and
lymph node metastasis). Pin1 is believed to have statisti-
cally significantly correlated with the PTC clinical stages.
Further study is required for understanding its patho-
genesis, and determining the precise role the Pin1 plays
in PTC cell cycle proceeding, which could have import-
ant meaning in the diagnostics and treatments in PTCs.
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